标题
Vedolizumab for the treatment of ulcerative colitis and Crohn’s disease
作者
关键词
-
出版物
Immunotherapy
Volume 4, Issue 9, Pages 883-898
出版商
Future Medicine Ltd
发表日期
2012-10-10
DOI
10.2217/imt.12.85
参考文献
相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。- 943b Induction Therapy for Ulcerative Colitis: Results of GEMINI I, a Randomized, Placebo-Controlled, Double-Blind, Multicenter Phase 3 Trial
- (2015) B.G. Feagan et al. GASTROENTEROLOGY
- Treatment of inflammatory bowel disease (IBD)
- (2014) Anand B. Pithadia et al. Pharmacological Reports
- Hospitalisations and surgery in Crohn's disease
- (2012) Charles N Bernstein et al. GUT
- Structural specializations of α4β7, an integrin that mediates rolling adhesion
- (2012) Yamei Yu et al. JOURNAL OF CELL BIOLOGY
- Randomised clinical trial: improvement in health outcomes with certolizumab pegol in patients with active Crohn’s disease with prior loss of response to infliximab
- (2011) B. G. Feagan et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Review article: loss of response to anti-TNF treatments in Crohn’s disease
- (2011) S. Ben-Horin et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Review article: remission rates achievable by current therapies for inflammatory bowel disease
- (2011) L. Peyrin-Biroulet et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Efficacy of Biological Therapies in Inflammatory Bowel Disease: Systematic Review and Meta-Analysis
- (2011) Alexander C Ford et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Methotrexate: A Drug of the Future in Ulcerative Colitis?
- (2011) Franck Carbonnel CURRENT DRUG TARGETS
- Emerging immunological targets in inflammatory bowel disease
- (2011) Giovanni Monteleone et al. CURRENT OPINION IN PHARMACOLOGY
- Increasing Incidence and Prevalence of the Inflammatory Bowel Diseases With Time, Based on Systematic Review
- (2011) Natalie A. Molodecky et al. GASTROENTEROLOGY
- The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study
- (2011) S. Vermeire et al. GUT
- Vedolizumab for the Treatment of Active Ulcerative Colitis: A Randomized Controlled Phase 2 Dose-ranging Study
- (2011) Asit Parikh et al. INFLAMMATORY BOWEL DISEASES
- Antibody-based therapeutics to watch in 2011
- (2011) Janice M. Reichert mAbs
- Bases moleculares de las interacciones leucocito-endotelio durante la respuesta inflamatoria
- (2011) Olga Barreiro et al. REVISTA ESPANOLA DE CARDIOLOGIA
- Optimizing clinical use of mesalazine (5-aminosalicylic acid) in inflammatory bowel disease
- (2011) Chadwick Williams et al. Therapeutic Advances in Gastroenterology
- Targeting leukocyte migration and adhesion in Crohn’s disease and ulcerative colitis
- (2011) Saskia Thomas et al. INFLAMMOPHARMACOLOGY
- Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
- (2010) Waqqas Afif et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Appropriate infliximab infusion dosage and monitoring: results of a panel meeting of rheumatologists, dermatologists and gastroenterologists
- (2010) Hilbert S. De Vries et al. BRITISH JOURNAL OF CLINICAL PHARMACOLOGY
- Leukocyte traffic control: a novel therapeutic strategy for inflammatory bowel disease
- (2010) Gionata Fiorino et al. Expert Review of Clinical Immunology
- Leukocytoclastic vasculitis
- (2010) Sami Karoui et al. INFLAMMATORY BOWEL DISEASES
- Inflammatory bowel disease-attributable costs and cost-effective strategies in the United States
- (2010) K. T. Park et al. INFLAMMATORY BOWEL DISEASES
- Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
- (2010) Jean Frédéric Colombel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy of methotrexate in Crohn’s disease and ulcerative colitis patients unresponsive or intolerant to azathioprine /mercaptopurine
- (2009) M. WAHED et al. ALIMENTARY PHARMACOLOGY & THERAPEUTICS
- Comparison of Two Adalimumab Treatment Schedule Strategies for Moderate-to-Severe Crohn's Disease: Results From the CHARM Trial
- (2009) Jean-Frédéric Colombel et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Anti-Adhesion Molecule Strategies for Crohn Disease
- (2009) Yvette Leung et al. BIODRUGS
- S1066 Oral Alpha-4 Integrin Inhibitor (AJM300) in Patients with Active Crohn's Disease — A Randomized, Double-Blind, Placebo-Controlled Trial
- (2009) Masakazu Takazoe et al. GASTROENTEROLOGY
- Rare Neurological Condition Linked to Newer Monoclonal Antibody Biologics
- (2009) Bridget M. Kuehn JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- The Binding Specificity and Selective Antagonism of Vedolizumab, an Anti- 4 7 Integrin Therapeutic Antibody in Development for Inflammatory Bowel Diseases
- (2009) D. Soler et al. JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
- Adverse Events Associated With the Use of Cyclosporine in Patients With Inflammatory Bowel Disease
- (2008) Michael B. Sternthal et al. AMERICAN JOURNAL OF GASTROENTEROLOGY
- Efficacy and safety of certolizumab pegol monotherapy every 4 weeks in patients with rheumatoid arthritis failing previous disease-modifying antirheumatic therapy: the FAST4WARD study
- (2008) R Fleischmann et al. ANNALS OF THE RHEUMATIC DISEASES
- Formation of antibodies against infliximab and adalimumab strongly correlates with functional drug levels and clinical responses in rheumatoid arthritis
- (2008) T R D J Radstake et al. ANNALS OF THE RHEUMATIC DISEASES
- Treatment of Active Crohn's Disease With MLN0002, a Humanized Antibody to the α4β7 Integrin
- (2008) Brian G. Feagan et al. Clinical Gastroenterology and Hepatology
- Extraintestinal manifestations of inflammatory bowel disease
- (2008) S. Ardizzone et al. DIGESTIVE AND LIVER DISEASE
- Direct Health Care Costs of Crohn's Disease and Ulcerative Colitis in US Children and Adults
- (2008) Michael D. Kappelman et al. GASTROENTEROLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More